Common and rare variants associated with body mass index (BMI) and obesity account for <5% of the variance in BMI. We performed SNP and copy number variation (CNV) association analyses in 1,509 children with obesity at the extreme tail (>3 s.d. from the mean) of the BMI distribution and 5,380 controls. Evaluation of 29 SNPs (P < 1 × 10 −5 ) in an additional 971 severely obese children and 1,990 controls identified 4 new loci associated with severe obesity (LEPR, PRKCH, PACS1 and RMST). A previously reported 43-kb deletion at the NEGR1 locus was significantly associated with severe obesity (P = 6.6 × 10 −7 ). However, this signal was entirely driven by a flanking 8-kb deletion; absence of this deletion increased risk for obesity (P = 6.1 × 10 −11 ). We found a significant burden of rare, single CNVs in severely obese cases (P < 0.0001). Integrative gene network pathway analysis of rare deletions indicated enrichment of genes affecting G protein-coupled receptors (GPCRs) involved in the neuronal regulation of energy homeostasis.
Within a population that shares the same environment, a significant proportion of the variance in BMI is genetically determined 1 . Meta-analyses of genome-wide association studies (GWAS) for obesity-related traits (including BMI, waist-to-hip ratio and obesity) have led to the discovery of at least 52 loci so far 2 . However, the fraction of BMI variance that can be attributed to common SNPs is, at the most, 2% (ref. 2) . Candidate gene studies in severe obesity have led to the identification of several rare, highly penetrant mutations involving the hypothalamic leptin-melanocortin pathway, with variants in the MC4R gene (encoding the melanocortin 4 receptor) being the most common, with a population prevalence of 1 in 1,000 (ref. 1) . Although epistatic and gene-environment interactions may contribute to the unexplained heritability of obesity 3 , it seems likely that a significant fraction is due to missing loci or established loci that have not yet been fully characterized.
As studying individuals at the extremes of a quantitative phenotype distribution has established usefulness 4 , we performed a GWAS in 1,509 UK children of European ancestry with severe early-onset obesity (SCOOP) and 5,380 Wellcome Trust Case Control Consortium 2 (WTCCC2) UK controls 5 to identify new associations of common and low-frequency SNPs and CNVs with obesity (Online Methods). Analysis of ~2 million directly genotyped or imputed SNPs, under a log-additive model, identified 29 loci with evidence of association Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity npg l e t t e r s with obesity (P < 1 × 10 −5 ) (Supplementary Table 1 ). These 29 SNPs were taken forward for validation in 971 additional severely obese children and 1,990 controls (Online Methods). Joint analysis of discovery and validation stages, including up to 2,480 cases and 7,370 controls, identified 9 genome-wide significant signals in 8 loci (P < 5 × 10 −8 ; Fig. 1 and Table 1 ). Three mapped in or near PRKCH, PACS1 and RMST and have not been previously associated with obesity ( Figs. 1  and 2 ). These genes are ubiquitously expressed ( Supplementary  Fig. 1) , and, so far, their role in energy homeostasis is unknown. A notable finding was that of a new association with an intermediatefrequency allele (rs11208659, 6% minor allele frequency (MAF) in the CEU HapMap population (Utah residents of Northern and Western European ancestry)) in the LEPR gene encoding the leptin receptor. Homozygous loss-of-function LEPR variants can lead to monogenic obesity 1 . To test whether this signal was driven by rare causal mutations, we sequenced all cases carrying at least 1 predisposing (C) allele for whom DNA was available (286/295); none had homozygous LEPR mutations, and the 3 rare nonsynonymous changes identified are unlikely to be sufficient to drive the association signal (data not shown), arguing against the LEPR signal being driven by causal mutations and suggesting that a more common LEPR allele can influence predisposition to severe obesity. An analysis collapsing directly genotyped low-frequency SNPs (MAF < 5%) across the discovery sample set did not find a statistically significant accumulation of rare SNPs in any locus apart from LEPR. However, the rare variant association signal at the LEPR locus was driven by the lead SNP (rs11208659): adjusting for this SNP abolished the association signal (data not shown). We also found that the risk allele (C) at the LEPR locus was associated with lower LEPR expression in monocytes 6 (P = 0.0321; Supplementary Fig. 2 ). Given the established importance of LEPR-mediated signaling in energy homeostasis, this finding suggests that the association with obesity may be mediated by reduction in the levels of LEPR expression. The remaining four obesity-associated loci (in or near FTO, MC4R, TMEM18 and NEGR1) have been reported previously 2 . As our cases lie at the very extreme end of the BMI distribution, there are very few other cohorts of sufficient size and comparable severity of obesity for replication. Consistent with this, on comparing our genome-wide significant results to those of other GWAS for childhood obesity 7, 8 and for varying degrees of obesity in adults and children [9] [10] [11] [12] [13] [14] [15] [16] (Supplementary Table 2 ), we found that there was relatively little overlap, other than for FTO, TMEM18 and MC4R. To explore the differences between our results and those from a large-scale meta-analysis of BMI in population-based cohorts, we compared our results with those obtained by the Genetic Investigation of ANthropometric Traits (GIANT) Consortium (Supplementary Figs. 3 and 4 and Supplementary Tables 3 and 4) . For several loci identified in GIANT analysis, we did not obtain genome-wide significant support for association in our cohort with severe early-onset obesity, although 14 loci showed directionally consistent associations at nominal significance levels (P < 0.05), more than expected by chance (P binomial = 6.10 × 10 −5 ; Supplementary Fig. 4 and Supplementary Table 4) . Some of these differences in association are accounted for by differences in power, as our sample size was much smaller than that in GIANT analysis; power calculations showed that we had <80% power to detect signals other than those in FTO, TMEM18 and MC4R at genome-wide levels of significance (Online Methods). This observation may also reflect differences in susceptibility to early-onset versus adult-onset obesity or in alleles associated with BMI in the obese versus severely obese ranges (Supplementary Table 2) . Indeed, the data suggest that, although there is significant overlap between the loci influencing BMI Genome-wide loci for association with severe early-onset obesity aligned to the risk-increasing (effect) allele. SNPs rs12463617, rs1993709, rs11208659, rs11109072 and rs3101336 were imputed. Chr., chromosome; EAF, effect allele frequency.
a Positions according to Build 36. b rs2168711 was used as a proxy in the follow-up stage.
npg l e t t e r s and common obesity and those influencing severe obesity, this overlap is incomplete, and the relative contribution of each locus to common and severe forms of obesity also differs. For example, although FTO is the locus with the largest reported effect size in several population studies, our results show that there are other loci with comparable or greater effect size on severe early-onset obesity ( Table 1) . Also, whereas NEGR1 (tagging the 40-kb deletion) and SH2B1 both had similar effect sizes in GIANT analysis, the effect of SH2B1 was much smaller in SCOOP ( Supplementary Fig. 4 and Supplementary Table 4) . Construction of a risk score with the SNPs from the GIANT study 17 that were available in our data also suggested that the severely obese cases seen in SCOOP do not have an increased burden of established loci for BMI (mean risk score = 27.2), suggesting that their severe obesity may be due to different risk alleles. Similarly, data from the GIANT analysis do not support the association of the new SCOOP loci with BMI in population-derived cohorts ( Supplementary Fig. 3 and Supplementary Table 3) . However, in the recent GIANT discovery sample (n = 123,865), only 167 individuals would have a comparable BMI to SCOOP cases; therefore, the lack of replication does not preclude an effect of these variants on severe obesity.
We analyzed the SNP data to examine whether there was an excess in cases of homozygosity by descent (HBD), either across the genome or in specific genomic locations (Online Methods). We did not observe any significant genome-wide homozygosity burden in cases (Supplementary Fig. 5 ). When the distribution of regions of HBD across individual genes was considered, there were a number of overlapping regions across genes on chromosomes 2, 8 and 10 with nominal evidence of an excess of HBD in cases (P < 0.01), although these did not survive correction for multiple testing ( Supplementary  Fig. 5 ). These findings suggest, that individually and cumulatively, homozygously acting genes are unlikely to have a major role in the etiology of severe obesity in our outbred UK cohort.
We assessed the role of common and rare CNVs in severe early-onset obesity. Our strongest association signal (P = 6.1 × 10 −11 ), also supported by the SNP data, was of a protective ~8-kb deletion upstream of NEGR1, with a weaker positive association signal (P = 6.6 × 10 −7 ) from a larger, non-overlapping ~43-kb deletion (72,541-72,584 kb) flanking the ~8-kb deletion (Fig. 3) . These deletions are known to segregate on distinct haplotypes, and, as the three alleles (43-kb deletion, 8-kb deletion and undeleted) are mutually exclusive, we tested whether Figure 2 Regional association plots of the new loci. Plots were generated using LocusZoom 23 .
npg l e t t e r s the two deletion alleles were independently associated with severe obesity. The frequency of the undeleted allele was approximately the same in cases and controls and was not associated with the phenotype (odds ratio (OR) = 1.00, 95% confidence interval (CI) = (0.90-1.10); P = 0.93, two-sided Fisher's exact test). When conditioned on the smaller deletion allele, the association of the larger deletion allele was completely abolished (OR = 1.09, 95 % CI = 0.97-1.22; P = 0.16). However, when conditioned on the larger deletion allele, the association of the smaller deletion allele remained significant (OR = 0.70, 95% CI = 0.60-0.82; P = 6.93 × 10 −6 ), suggesting that the association signal at the NEGR1 locus in our cohort is largely driven by the protective effect of the ~8-kb deletion allele. In keeping with these results, we found that the SNP with the strongest association signal for obesity at this locus (rs1993709) tagged the 8-kb deletion (Table 1) , and conditional analyses performed at the SNP level were consistent with these findings (data not shown), highlighting the strength of the combined SNP and CNV analysis.
Although the 8-kb deletion does not disrupt the coding sequence of any gene, it encompasses a single conserved transcription factor binding site for NKX6.1 (ref. 18) (Fig. 4a,b) , which is known to be involved in neuronal development in the mid-and hindbrain. We used electrophoretic mobility shift assays (EMSAs) to confirm binding of NKX6.1 to its predicted binding site in the region corresponding to the 8-kb deletion (Fig. 4c) . NKX6.1 is a potent transcriptional repressor, such that loss of binding would be predicted to lead to greater gene expression. In existing expression quantitative trait locus (eQTL) data, the small deletion seemed to be associated with greater expression of NEGR1 in lymphoblastoid cell lines (P = 0.0427; Supplementary  Fig. 6 ). Further studies will be needed to establish whether NEGR1 is transcriptionally regulated by NKX6.1 in relevant human tissues. As NEGR1 is involved in neurite outgrowth 19 , a process known to be involved in human obesity 1 , these observations could form the basis for a molecular explanation for this association, which needs to be formally tested.
We previously demonstrated a significant burden of large rare deletions in individuals with severe early-onset obesity and developmental delay 20 . Here, we used a permutation-based method to assess the statistical significance of genome-wide CNV burden (Online Methods). A significant enrichment in cases was observed for all CNVs >100 kb in size and <1% in frequency ( Table 2 and Supplementary Table 5 ). The most significant enrichment was observed in duplications in the range of 100-200 kb and deletions >100 kb in size. The enrichment of singleton CNVs was stronger than that of rare recurrent CNVs (1.8-fold higher; P = 0.0001). We focused on the large number (765) of obesity-specific deletions that were not detected in controls. Although CNVs may contribute to disease by affecting regulatory regions of the genome, given the large number of rare CNVs identified in this study, we focused on the CNVs that disrupted the exon sequences of 490 genes (in 336 cases) where we could more directly infer pathogenicity due to dosage sensitivity. To examine whether these 490 genes converged on specific biological pathways, we conducted pathway enrichment analysis using Ingenuity Pathways Analysis (IPA); genes involved in nervous system development and/or function were significantly overrepresented (P = 9.83 × 10 −5 ) (Supplementary Table 6 ). The most significant enrichment involved a network of 13 genes encoding GPCRs ( Supplementary Fig. 7) ; these CNVs were validated by an independent method, multiplex ligation-dependent probe amplification (MLPA) (data not shown). Several of the genes disrupted by these CNVs have an important role in energy homeostasis in animals, including OPRM1 (µ-opioid receptor 1), FSHR (follicle-stimulating hormone receptor) The nucleotide percent identity plot (PIP) for the region is shown. Orthologous sequences from multiple species were aligned to the human sequence using MultiPIP maker, and sequence identities of >50% (light gray) and >75% (dark gray) are highlighted, with the details (for sequence identities of >50%) shown below. The predicted NKX6.1-binding site is located in the most conserved region (arrow). (c) Transcription factor NKX6.1 binding was confirmed using EMSAs. A shift in electrophoretic mobility (arrow) was specific to the sequence contained in the 8-kb deletion. NS, nonspecific band.
npg l e t t e r s and OXTR (oxytocin receptor). In addition, genetic variation in the DRD2 gene (encoding dopamine receptor D 2 ) has been associated with eating behavior and brain activation responses to images of food in humans 21 . We independently analyzed the same data set using another method that corrects for CNV size 22 and replicated the observation that rare CNVs deleting genes encoding GPCRs were significantly associated with severe obesity (Supplementary Table 7 ).
In conclusion, by combining SNP and CNV analysis and focusing on severe obesity, we have identified four new obesity susceptibility loci, including an intermediate-frequency variant in LEPR. These findings add to the body of evidence suggesting that both common and rare variants around specific genes or loci (LEPR, POMC, MC4R, BDNF and SH2B1) are involved in the pathogenesis of obesity. We show that there is an incomplete overlap between the loci influencing risk of severe obesity and those that influence more common obesity, detected by studies in population-based cohorts, and that the relative contribution of each locus to severe versus common obesity also differs. Furthermore, we provide evidence that severe obesity without developmental delay is associated with a significantly greater burden of rare, typically singleton CNVs, in parallel with findings in intellectual disability. Using pathway analysis, we found that rare CNVs that delete genes involved in the neuronal regulation of energy homeostasis contribute to severe obesity; looking for rare coding variants in these genes may be fruitful. As we observed a significant enrichment for CNVs that deleted GPCRs, which are key targets for drug development, these findings may have potential therapeutic implications. 
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Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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We are indebted to the subjects and their families for their participation and to the physicians involved in the Genetics of Obesity Study (GOOS npg compares the goodness of fit with or without association to affected status. Test P values could be obtained for 481 of the 587 common CNVEs, whereas the rest could not be run through CNV tools owing to poor genotype clustering. For further analysis of NEGR1 deletions, association tests were performed using Fisher's exact test based on discrete genotype calls, as the distribution of CNV measures of both cases and controls were in distinct and nonoverlapping copy number clusters.
Rare CNV burden. Conditional permutation tests 20 were performed to test the hypothesis that cases exhibit a greater burden of rare (carrier frequency < 1%) and large (>100 kb) CNVs relative to controls. Statistical significance was established by 10,000 rounds of permutation.
Biological pathway enrichment analysis. Using the Database for Annotation, Visualization and Integrated Discovery (DAVID; see URLs), gene lists were mapped onto curated biological process gene categories using Gene Ontology (GO; The Gene Ontology Consortium). Gene lists were also mapped to pathways and biological processes using the PANTHER classification system (see URLs) and IPA (version 9.0, Ingenuity Systems; see URLs). The most significantly enriched categories of molecules and pathways (smallest P values, P < 0.05) were identified using these tools.
EMSAs. Perfect-match (wild-type) or mutated oligonucleotides to the predicted NKX6.1-binding site within the 8-kb deletion were designed (Supplementary Table 8 ) and used in EMSAs. Non-radioactive chemiluminescent detection was employed, specifically the Light Shift Chemiluminescent EMSA kit (Thermo Fisher Scientific). Briefly, labeled or unlabeled oligonucleotides were incubated with cell lysates from HEK293 cells expressing the human NKX6.1 protein (Novus Biologicals , NBL1-13663), in the presence or absence of an antibody to NKX6.1 (Abcam, ab90706). DNA-protein complexes were run on 4% DNA retardation polyacrylamide gels (Invitrogen) and transferred to a nylon membrane using iBlot DNA transfer stacks and an iBlot transfer system (Invitrogen), and the resulting chemiluminescence was detected by exposure to X-ray film (Kodak).
